RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

The T4 and T4A reporting requirements for employer- and payer-offered dental benefits, for issuers who would otherwise enter code 1, are waived again for 2024. This Canadian Dental Care Plan (CDCP) ...

Saskatchewan Blue Cross, a leading health and wellness solutions provider, is dedicated to making a meaningful difference in ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

billion (1.4 billion euros). Roche, the world's number-one oncology group, will offer Poseida shareholders $9.0 per share and add a further $4.0 per share by way of a non-tradeable certificate to ...

Contineum Therapeutics, Inc. Class A ( (CTNM)) has released its Q3 earnings. Here is a breakdown of the information Contineum Therapeutics, Inc. Class A presented to its investors. Don't Miss our ...

as well as expanding its portfolio of product candidates due to the acquisition of Aliada Therapeutics at the end of October 2024 and Cerevel Therapeutics. Ultimately, due to the anticipated ...

It is currently in the process of acquiring Aliada Therapeutics for $1.4 billion, primarily for its Alzheimer’s treatment in the pipeline. Looking forward, we expect both AbbVie and J&J’s ...